Breast Development Timelines on Feminising Therapy

Evidence Note

What is the question?

Really two questions. When does breast growth start, peak and settle — and how much growth to expect. The first has decent prospective data behind it. The second has an honest answer many sources avoid: no one can predict it in advance.

What does the evidence say?

When it starts. Growth usually begins around three to six months after starting therapy.

When most of it happens. The largest measured changes come in the first year, much of it within the first six months. Growth then slows, but does not stop.

What happens after the first year. In three-year prospective follow-up, the simple tape-measure (breast–chest) difference plateaued at around nine months, while breast volume measured by 3D imaging kept increasing, more gradually, across the full three years. Older consensus tables describe gradual change continuing to around two to three years, reaching a typical Tanner stage of 2–3.

How much. Modest, on average, and below the cisgender female average. In the largest prospective study, the mean breast–chest difference increased by about 7.9 cm after one year, and nearly half of participants (around 49%) had less than an AAA cup at one year.

Why it varies. This is the striking part: no measurable factor reliably predicts final size — not oestradiol level, not any other blood or clinical parameter. One caveat bounds even that finding: the studies measured total serum oestradiol, not the free (bioavailable) fraction that SHBG shifts, so the variable most likely to matter biologically was not the one measured.

It is permanent. Breast tissue that develops is one of the irreversible effects of feminising therapy.

How strong is the evidence?

Moderate — and that is deliberately a step above most feminising outcomes. Breast development is the best-measured feminising change, with prospective multicentre data using both tape-measure and 3D imaging. Where the evidence runs out is prediction: the timeline is reasonably well characterised, but what determines an individual’s final size is not.

Where are the uncertainties?

Why breast size varies so much between people is genuinely unknown — no predictor has been found. Whether the free oestradiol fraction (via SHBG) is part of the answer is plausible but untested, because the studies measured total, not free, oestradiol. And whether adding progesterone increases breast growth is not established: guidelines found no quality evidence, and the first randomised trial has so far reported only preliminary, not-yet-peer-reviewed results (covered in a separate review).

The timeline is one of the best-measured things in feminising care. The final size is one of the least predictable.

What does this mean for practice?

A few things are worth carrying in. Expect a timeline more than a size: most growth over the first year, continuing more gradually after. Do not expect a bigger dose to mean bigger breasts — once testosterone is well suppressed, higher oestradiol has not been shown to add breast growth, and mainly adds risk. Because final size cannot be predicted or hurried, and because breast tissue is permanent, some people later choose augmentation — a normal, planned part of many paths, not a sign that therapy failed. As always, dose and route are decisions made with a clinician, for the whole body rather than one outcome.